TickerFacts.

Endonovo Therapeutics, Inc. (ENDV): Cost of Revenue

Annual figures by period end, from SEC filings.

Not updated since 2022-12-31. No annual report in US GAAP has been filed since. Companies that switch to IFRS reporting, as many foreign filers do, or stop filing are not updated here.

$10.0K
Year ended 2022-12-31
-52.5%
3-year compound annual growth
$93.4K2018-12-31: $12.9K2019-12-31: $93.4K2020-12-31: $65.4K2021-12-31: $15.0K2022-12-31: $10.0K$10.0K
2018-12-31 Cost of Revenue (USD) 2022-12-31
Period endedCost of RevenueChange YoYSource filing
2022-12-31$10.0K-33.3%2023-04-17, From 2022-01-01
2021-12-31$15.0K-77.1%2023-04-17, From 2021-01-01
2020-12-31$65.4K-30.0%2022-04-14, From 2020-01-01
2019-12-31$93.4K+622.2%2021-04-13, From 2019-01-01
2018-12-31$12.9Kn/a2020-05-04, From 2018-01-01